Why are amlodipine and low-dose aspirin (ASA) prescribed together for hypertension with cardiovascular risk?

Why Amlodipine and Aspirin Are Prescribed Together

For patients with hypertension and high cardiovascular risk, combining amlodipine with low-dose aspirin (75-100 mg daily) provides dual benefit: amlodipine effectively lowers blood pressure while aspirin reduces thrombotic cardiovascular events, and importantly, aspirin does not interfere with amlodipine's antihypertensive effect.

Blood Pressure Control with Amlodipine

Amlodipine is a dihydropyridine calcium channel blocker that effectively reduces blood pressure through vascular smooth muscle relaxation 1. The ACCOMPLISH trial demonstrated that ACE inhibitor/amlodipine combinations were superior to ACE inhibitor/thiazide combinations in high-risk hypertensive patients, reducing cardiovascular death, myocardial infarction, and stroke by 21% (RR 0.79; 95% CI 0.67 to 0.92) 2.

Key advantages of amlodipine include:

• Long half-life (35-50 hours) providing 24-hour blood pressure control
• Maintains effect even with missed doses
• No adverse effects on glycemic control or renal function
• Effective in elderly patients and those with diabetes 3

Cardiovascular Protection with Aspirin

Low-dose aspirin (75-100 mg daily) is recommended for cardiovascular event prevention in hypertensive patients at elevated risk 4. In the Hypertension Optimal Treatment (HOT) trial, aspirin 75 mg daily reduced major cardiovascular events by 15% and myocardial infarction by 36% in well-controlled hypertensive patients 4.

Who Should Receive Aspirin

Aspirin should be considered for hypertensive patients who meet these criteria 4:

• 10-year cardiovascular disease risk ≥15% (primary prevention)
• Established cardiovascular disease (secondary prevention)
• Multiple cardiovascular risk factors
• Diabetes mellitus with hypertension
• Elevated serum creatinine >1.3 mg/dl

The 2011 ACC/AHA guidelines note that antiplatelet therapy is recommended for hypertensive patients with cardiovascular events, and may be considered in those without prior events but with reduced renal function or high cardiovascular risk 5.

Critical Drug Interaction Evidence

A major concern historically was whether aspirin interferes with antihypertensive efficacy. The HOT study definitively addressed this: aspirin 75 mg daily did not interfere with blood pressure control achieved by antihypertensive agents, including ACE inhibitors 6. In 18,790 patients followed for 3.8 years:

• Systolic and diastolic blood pressures were identical between aspirin and placebo groups
• Similar antihypertensive medication requirements in both groups
• No differences in renal function or creatinine clearance
• Cardiovascular benefits of aspirin were maintained regardless of ACE inhibitor use 6

Important Caveat on ACE Inhibitor Interaction

While the HOT study showed no interaction with low-dose aspirin, there remains theoretical concern about aspirin attenuating ACE inhibitor benefits through prostaglandin inhibition 7. However, a systematic overview of 22,060 patients from 6 trials found ACE inhibitors provided significant benefit in patients both with and without aspirin (20% vs 29% risk reduction, difference not statistically significant) 7.

If concerned about this interaction, clopidogrel is an alternative antiplatelet agent that does not interact with ACE inhibitors, though it lacks indication for primary prevention 7.

Safety Considerations

The benefit-to-harm ratio favors combination therapy in appropriate patients 8:

Benefits:

• Superior blood pressure control
• Reduced cardiovascular events and myocardial infarction
• Stroke prevention

Risks:

• Increased major bleeding (65% increase in HOT trial, but absolute numbers remained low) 4
• Aspirin should only be used when blood pressure is adequately controlled
• Higher bleeding risk must be weighed against cardiovascular benefit

The number of major bleeding episodes was similar to the number of cardiovascular events prevented, making patient selection critical 4.

Practical Algorithm for Use

1. Establish hypertension diagnosis and cardiovascular risk

   • Calculate 10-year cardiovascular risk
   • Assess for diabetes, renal disease, established CVD

2. Initiate amlodipine for blood pressure control

   • Start 5 mg daily, titrate to 10 mg if needed 1
   • May combine with ACE inhibitor or ARB for high-risk patients 2

3. Add aspirin 75-100 mg daily if:

   • Blood pressure adequately controlled (<140/90 mmHg)
   • AND 10-year CVD risk ≥15%, OR
   • Established cardiovascular disease, OR
   • Diabetes with additional risk factors, OR
   • Serum creatinine >1.3 mg/dl 4, 8

4. Monitor for:

   • Blood pressure control (target <140/90 mmHg, <130/80 mmHg in diabetes/CKD)
   • Bleeding complications
   • Peripheral edema (common with amlodipine, especially 10 mg dose)

Common Pitfalls to Avoid

• Do not use aspirin for primary prevention in low-risk hypertensive patients - bleeding risk outweighs benefit 4
• Do not add aspirin before blood pressure is controlled - increased bleeding risk without established benefit
• Do not use high-dose aspirin - evidence supports only 75-100 mg daily; higher doses increase bleeding without additional cardiovascular benefit 9
• Do not discontinue aspirin in patients with established CVD - secondary prevention benefits are well-established 10

The combination of amlodipine and low-dose aspirin represents evidence-based therapy for hypertensive patients at elevated cardiovascular risk, with complementary mechanisms addressing both hemodynamic and thrombotic pathophysiology 11, 12.